[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201808821WA - Agonistic antibodies that bind human cd40 and uses thereof - Google Patents

Agonistic antibodies that bind human cd40 and uses thereof

Info

Publication number
SG11201808821WA
SG11201808821WA SG11201808821WA SG11201808821WA SG11201808821WA SG 11201808821W A SG11201808821W A SG 11201808821WA SG 11201808821W A SG11201808821W A SG 11201808821WA SG 11201808821W A SG11201808821W A SG 11201808821WA SG 11201808821W A SG11201808821W A SG 11201808821WA
Authority
SG
Singapore
Prior art keywords
international
road
pct
agonistic antibodies
antibodies
Prior art date
Application number
SG11201808821WA
Inventor
Tibor Keler
Joel Goldstein
Laura Vitale
Lizhen He
Tom O'neill
Andrea Crocker
Karuna Sundarapandiyan
Lawrence Thomas
Jenifer Widger
Original Assignee
Celldex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celldex Therapeutics Inc filed Critical Celldex Therapeutics Inc
Publication of SG11201808821WA publication Critical patent/SG11201808821WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111011111111101 IIIIIIIIIIIIIIIIIII101110111110111111111110111110111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/184619 A2 26 October 2017 (26.10.2017) WIPO I PCT (51) International Patent Classification: C07K 16/28 (2006.01) Published: — without international search report and to be republished (21) International Application Number: upon receipt of that report (Rule 48.2(g)) PCT/US2017/028162 (22) International Filing Date: 18 April 2017 (18.04.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/324,170 18 April 2016 (18.04.2016) US (71) Applicant: CELLDEX THERAPEUTICS, INC. [US/US]; 119 Fourth Avenue, Needham, MA 02494-2725 (US). (72) Inventors: KELER, Tibor; 198 Cafferty Road, Pipersville, PA 18947-1613 (US). GOLDSTEIN, Joel; 77 Lam- bertville Hopewell Rd., Hopewell, NJ 08525 (US). VI- — TALE, Laura, A.; 5574 Bittersweet Lane, Doylestown, PA 18902 (US). HE, Lizhen; 1675 Ridgeview Drive, Allen- - = town, PA 18104 (US). O'NEILL, Tom; 2 Foundry Lane, Washington, NJ 07882 (US). CROCKER, Andrea; 298 Windy Bush Road, New Hope, PA 18938 (US). SUN- = DARAPANDIYAN, Karuna; 38 Village Road, Kendall - = Park, NJ 08824 (US). THOMAS, Lawrence, J.; 1 Fox Ridge Road, Easton, MA 02375 (US). Agent: REMILLARD, Jane, E. et al.; Nelson Mullins Ri- ley & Scarborough LLP, One Post Office Square, Boston, MA 02109-2127 (US). = (74) Designated States (unless otherwise indicated, for every (81) = kind of national protection available): AE, AG, AL, AM, _ AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = _ CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, = = PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, = — SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, = TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, — ei 1-1 V::+ TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 71' GC KM, ML, MR, NE, SN, TD, TG). 1-1 IN 1-1 (54) Title: AGONISTIC ANTIBODIES THAT BIND HUMAN CD40 AND USES THEREOF © ei (57) : Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and 0 molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
SG11201808821WA 2016-04-18 2017-04-18 Agonistic antibodies that bind human cd40 and uses thereof SG11201808821WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662324170P 2016-04-18 2016-04-18
PCT/US2017/028162 WO2017184619A2 (en) 2016-04-18 2017-04-18 Agonistic antibodies that bind human cd40 and uses thereof

Publications (1)

Publication Number Publication Date
SG11201808821WA true SG11201808821WA (en) 2018-11-29

Family

ID=58664791

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201808821WA SG11201808821WA (en) 2016-04-18 2017-04-18 Agonistic antibodies that bind human cd40 and uses thereof
SG10201913248VA SG10201913248VA (en) 2016-04-18 2017-04-18 Agonistic antibodies that bind human cd40 and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913248VA SG10201913248VA (en) 2016-04-18 2017-04-18 Agonistic antibodies that bind human cd40 and uses thereof

Country Status (14)

Country Link
US (5) US20200377606A1 (en)
EP (1) EP3445783A2 (en)
JP (2) JP7038064B2 (en)
KR (1) KR102414558B1 (en)
CN (2) CN109071665B (en)
AU (1) AU2017252527A1 (en)
BR (1) BR112018071307A2 (en)
CA (1) CA3021328A1 (en)
EA (1) EA201892362A1 (en)
IL (1) IL262269B2 (en)
MA (1) MA44723A (en)
MX (1) MX2018012757A (en)
SG (2) SG11201808821WA (en)
WO (1) WO2017184619A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA024701B1 (en) 2010-04-13 2016-10-31 Селлдекс Терапьютикс Инк. Antibodies that bind human cd27 and uses thereof
SG11201808821WA (en) 2016-04-18 2018-11-29 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
CN115317603A (en) 2016-07-07 2022-11-11 小利兰·斯坦福大学托管委员会 Antibody adjuvant conjugates
MX2019003683A (en) 2016-10-11 2019-08-22 Agenus Inc Anti-lag-3 antibodies and methods of use thereof.
SG11202002366VA (en) * 2017-09-19 2020-04-29 Mab Discovery Gmbh Agonistic cd40 antibodies
CN118852460A (en) * 2017-12-28 2024-10-29 尤利乌斯·马克西米利安维尔茨堡大学 Tumor Necrosis Factor (TNF) receptor superfamily (TNFRSF) receptor-activating antibody fusion proteins having Fc-dependent agonistic activity (TNFRSF receptor-activating antibody fusion proteins having Fc-dependent agonistic activity; TRAAFFIAA)
CN109971717B (en) * 2017-12-28 2023-06-20 上海细胞治疗研究院 T cells co-expressing CD40 antibody and mesothelin specific chimeric antigen receptor and uses thereof
CN109971723B (en) * 2017-12-28 2023-07-07 上海细胞治疗研究院 T cells comprising CD40 antibody and muc1 specific chimeric antigen receptor gene and uses thereof
US20210198374A1 (en) 2018-04-17 2021-07-01 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
WO2019204756A1 (en) 2018-04-20 2019-10-24 Lyvgen Biopharma Co., Ltd. Anti-cd40 antibodies and uses thereof
AU2018432434A1 (en) 2018-07-20 2021-01-28 Eucure (Beijing) Biopharma Co., Ltd Anti-CD40 antibodies and uses thereof
KR20210070317A (en) 2018-09-28 2021-06-14 리브젠 바이오파마 코., 엘티디. Anti-CD40 binding molecules having engineered Fc domains and therapeutic uses thereof
CA3119865A1 (en) * 2018-11-23 2020-05-28 Strike Pharma Ab Bi-specific conjugates
CN109734813B (en) 2019-01-28 2022-06-17 广东昭泰体内生物医药科技有限公司 Chimeric antigen receptor and application thereof
CN111454361B (en) * 2019-03-04 2021-03-02 北京天广实生物技术股份有限公司 Antibodies that bind to CD40 and uses thereof
CN113993549A (en) 2019-03-15 2022-01-28 博尔特生物治疗药物有限公司 Immunoconjugates targeting HER2
US20220175920A1 (en) * 2019-03-27 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
CN113728008B (en) * 2019-04-10 2024-04-09 南开大学 anti-CD 40 antibodies and uses thereof
EP4027998A1 (en) 2019-09-09 2022-07-20 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
AR120832A1 (en) 2019-12-20 2022-03-23 Amgen Inc MULTISPECIFIC ANTIBODY CONSTRUCTS CD40 AGONISTS TARGETING MESOTHELIN FOR THE TREATMENT OF SOLID TUMORS
WO2021140222A1 (en) * 2020-01-10 2021-07-15 Symphogen A/S Anti-cd40 antibodies and compositions
TWI851885B (en) * 2020-03-30 2024-08-11 大陸商正大天晴藥業集團股份有限公司 Antibodies binding to CD40 and uses thereof
GB202008003D0 (en) * 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
WO2021257124A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
TWI799959B (en) * 2020-08-21 2023-04-21 大陸商上海藥明生物技術有限公司 CD40 agonist antibodies and methods of use
KR20230048112A (en) * 2020-08-21 2023-04-10 우시 바이올로직스 (상하이) 컴퍼니 리미티드 CD40 Agonizing Antibodies and Methods of Using The Same
CA3201588A1 (en) * 2020-12-09 2022-06-16 David Campbell Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
KR20230124672A (en) * 2020-12-23 2023-08-25 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Chlamydia vaccine based on targeting of MOMP VS4 antigen to antigen presenting cells
KR20230135620A (en) * 2021-01-29 2023-09-25 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Chlamydia trachomatis antigen polypeptides and their use for vaccine purposes
EP4377350A2 (en) 2021-07-28 2024-06-05 Genentech, Inc. Methods and compositions for treating cancer
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
CN118922450A (en) * 2022-04-02 2024-11-08 和铂医药(上海)有限责任公司 Antigen binding protein targeting CD40 and preparation and application thereof
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
FI861417A0 (en) 1985-04-15 1986-04-01 Endotronics Inc HEPATITIS B YTANTIGEN FRAMSTAELLD MED REKOMBINANT-DNA-TEKNIK, VACCIN, DIAGNOSTISKT MEDEL OCH CELLINJER SAMT FOERFARANDEN FOER FRAMSTAELLNING DAERAV.
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc LIPOSOMAS COUPLING METHOD.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5182368A (en) 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
EP0304578B1 (en) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide comprising hepatitis B surface antigen
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CN1074422C (en) 1987-11-18 2001-11-07 希龙股份有限公司 Nanbv diagnostics and vaccines
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990006951A1 (en) 1988-12-16 1990-06-28 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
HU225068B1 (en) 1989-03-17 2006-05-29 Chiron Corp Process for producing diagnostics and vaccine of nanbh
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
SG48175A1 (en) 1989-07-25 1998-04-17 Smithkline Beecham Biolog Novel antigens and method for their preparation
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
DE4123760C2 (en) 1991-07-18 2000-01-20 Dade Behring Marburg Gmbh Seroreactive areas on the HPV 16 proteins E1 and E2
ES2227512T3 (en) 1991-12-02 2005-04-01 Medical Research Council PRODUCTION OF ANTIBODIES AGAINST SELF-ANTIGENS FROM REPERTORIES OF ANTIBODY SEGMENTS FIXED IN A PHOTO.
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5620886A (en) 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE255906T1 (en) 1993-10-01 2003-12-15 Immunex Corp ANTIBODIES AGAINST CD40
ATE267607T1 (en) 1993-12-23 2004-06-15 Immunex Corp USE OF SOLUBLE OLIGOMERIC CD40 LIGANDS OR MONOCLONAL ANTIBODIES FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE PREVENTION OR TREATMENT OF NEOPLASTIC DISEASES
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
US7635479B2 (en) 2000-03-29 2009-12-22 The Trustees Of The University Of Pennsylvania Composition and methods for enhancing immunogenecity of antigens
EP0812358A1 (en) 1995-02-24 1997-12-17 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
KR19980702490A (en) 1995-03-01 1998-07-15 스티븐 엘. 말라스카 How to stimulate an immune response
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur Proteinase k resistant surface protein of neisseria meningitidis
US5840306A (en) 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6069233A (en) 1996-10-03 2000-05-30 Memorial Sloan-Kettering Cancer Center Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
JP2001523958A (en) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド CTLA-4 binding peptides for immunotherapy
EP0998557A2 (en) 1997-07-21 2000-05-10 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
IL138000A0 (en) 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
BRPI9916853B8 (en) 1998-12-23 2021-05-25 Abgenix Inc monoclonal antibody or an antigen-binding fragment thereof that specifically binds to cytotoxic t-lymphocyte antigen 4 (ctla-4) and nucleic acid
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
ATE353365T1 (en) 1999-08-23 2007-02-15 Dana Farber Cancer Inst Inc NEW B7-4 MOLECULES AND THEIR USES
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
WO2001039722A2 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
US6774226B1 (en) 1999-11-30 2004-08-10 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
US7063845B2 (en) * 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
JP2002088186A (en) * 2000-09-14 2002-03-27 Showa Highpolymer Co Ltd Method for producing flame-retardant phenolic resin foam
US6794501B2 (en) 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US20070098717A1 (en) 2003-11-04 2007-05-03 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
SI1682180T1 (en) 2003-11-04 2010-03-31 Novartis Vaccines & Diagnostic Antagonist anti-cd40 monoclonal antibodies and methods for their use
ATE516819T1 (en) 2003-11-04 2011-08-15 Novartis Vaccines & Diagnostic METHOD FOR TREATING B-CELL-RELATED CANCER
SI1684805T1 (en) 2003-11-04 2010-11-30 Novartis Vaccines & Diagnostic Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
WO2005044304A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CA2588613C (en) 2004-11-23 2010-09-14 Pip Co., Ltd. Built-in wall water service box
WO2006068953A2 (en) * 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
EP2161336B2 (en) 2005-05-09 2017-03-29 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
PL1879573T3 (en) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulators of indoleamine 2,3-dioxygenase and methods of using the same
PT1907424E (en) 2005-07-01 2015-10-09 Squibb & Sons Llc Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
ES2540561T3 (en) 2005-12-20 2015-07-10 Incyte Corporation N-hydroxyamidinoheterocycles as indolamine 2,3-dioxygenase modulators
WO2007130493A2 (en) * 2006-05-03 2007-11-15 Regents Of The University Of Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
EP2064207B1 (en) 2006-09-19 2013-11-06 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (en) 2006-09-19 2008-02-08 Incyte Corp COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS.
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
CA2667997C (en) 2006-11-02 2016-10-11 Genentech, Inc. Humanized anti-factor d antibodies and uses thereof
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
LT2188313T (en) 2007-08-21 2018-02-26 Amgen, Inc. Human c-fms antigen binding proteins
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
JP5583592B2 (en) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション IDO inhibitor
PT2234620E (en) 2008-01-03 2016-06-20 Université D`Aix-Marseille Tritherapy used to treat a patient infected by hiv
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
PT3009449T (en) 2008-07-16 2018-09-28 Inst Res Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
AU2009294416B2 (en) * 2008-09-19 2014-05-22 Medimmune Llc Antibodies against sonic hedgehog homolog and uses thereof
KR20180089573A (en) 2008-12-09 2018-08-08 제넨테크, 인크. Anti-pd-l1 antibodies and their use to enhance t-cell function
SG174344A1 (en) 2009-03-20 2011-11-28 Amgen Inc Alpha-4-beta-7 heterodimer specific antagonist antibody
WO2010108154A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Selective and potent peptide inhibitors of kv1.3
US20110007023A1 (en) 2009-07-09 2011-01-13 Sony Ericsson Mobile Communications Ab Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
KR101740171B1 (en) 2009-11-24 2017-05-25 메디뮨 리미티드 Targeted binding agents against b7-h1
CN105218672A (en) 2009-12-10 2016-01-06 霍夫曼-拉罗奇有限公司 Preferentially in conjunction with the antibody and uses thereof of people CSF1R extracellular domain 4
PT2542256T (en) 2010-03-04 2019-09-05 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
KR101647871B1 (en) 2010-03-05 2016-08-11 에프. 호프만-라 로슈 아게 Antibodies against human csf-1r and uses thereof
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
EP2566517B1 (en) 2010-05-04 2018-10-24 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CA2804550C (en) 2010-07-09 2021-01-05 Bionovion Holding B.V. Agonistic antibody to cd27
KR101527300B1 (en) 2010-09-09 2015-06-09 화이자 인코포레이티드 4-1bb binding molecules
WO2012096994A2 (en) 2011-01-10 2012-07-19 Emory University Antibodies directed against influenza
IT1403661B1 (en) * 2011-01-28 2013-10-31 Probiotical Spa EFFERVESCENT COMPOSITION IN THE SOLID FORM FOR USE IN VAGINAL APPLICATIONS FOR THE TREATMENT OF VAGINAL INFECTIONS.
US9133272B2 (en) * 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
NO2694640T3 (en) 2011-04-15 2018-03-17
JP6072771B2 (en) 2011-04-20 2017-02-01 メディミューン，エルエルシー Antibodies and other molecules that bind to B7-H1 and PD-1
KR101764096B1 (en) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 Anti-pd-l1 antibodies and uses thereof
CA2853889A1 (en) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
CN104093740B (en) 2012-02-06 2018-01-09 弗·哈夫曼-拉罗切有限公司 Use the composition and method of CSF1R inhibitor
WO2013130981A1 (en) 2012-03-02 2013-09-06 Regeneron Pharmaceuticals, Inc. Human antibodies to clostridium difficile toxins
AR090263A1 (en) 2012-03-08 2014-10-29 Hoffmann La Roche COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
EA030828B1 (en) 2012-03-15 2018-10-31 Янссен Байотек, Инк. Human anti-cd27 antibodies, methods and uses
JO3820B1 (en) 2012-05-03 2021-01-31 Regeneron Pharma Human antibodies to fel d1 and methods of use thereof
KR20150018533A (en) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csfir)
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
JP6136343B2 (en) 2012-06-12 2017-05-31 株式会社リコー Information processing system, information processing method, program, and recording medium
UY34887A (en) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
JP2015533787A (en) 2012-08-31 2015-11-26 ファイブ プライム セラピューティックス インコーポレイテッド Method of treating a condition with an antibody that binds colony stimulating factor 1 receptor (CSF1R)
ES2879552T3 (en) * 2012-10-30 2021-11-22 Apexigen Inc Anti-CD40 antibodies and methods of use
JO3532B1 (en) 2013-03-13 2020-07-05 Regeneron Pharma Anti-il-33 antibodies and uses thereof
SG11201506459PA (en) 2013-03-14 2015-09-29 Regeneron Pharma Human antibodies to grem 1
CN105189553A (en) 2013-03-14 2015-12-23 瑞泽恩制药公司 Human antibodies to nav1.7
EP3027210A1 (en) 2013-08-02 2016-06-08 Aduro Biotech Holdings, Europe B.V. Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
JP2016531920A (en) 2013-09-05 2016-10-13 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． CD70 binding peptides and related methods, processes and uses
KR102264548B1 (en) 2014-11-21 2021-06-16 삼성전자주식회사 Semiconductor packages and fabrication method thereof
CN116059344A (en) 2015-11-03 2023-05-05 詹森生物科技公司 Antibodies that specifically bind to PD-1 and uses thereof
SG11201808821WA (en) 2016-04-18 2018-11-29 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof

Also Published As

Publication number Publication date
US10633444B2 (en) 2020-04-28
CN116059351A (en) 2023-05-05
CN109071665A (en) 2018-12-21
IL262269A (en) 2018-11-29
US20180066053A1 (en) 2018-03-08
BR112018071307A2 (en) 2019-02-26
CN109071665B (en) 2022-11-01
JP2019521645A (en) 2019-08-08
SG10201913248VA (en) 2020-02-27
EA201892362A1 (en) 2019-04-30
WO2017184619A2 (en) 2017-10-26
EP3445783A2 (en) 2019-02-27
IL262269B2 (en) 2023-08-01
IL262269B1 (en) 2023-04-01
US20200369768A1 (en) 2020-11-26
JP7038064B2 (en) 2022-03-17
MA44723A (en) 2019-02-27
US20190322743A1 (en) 2019-10-24
WO2017184619A3 (en) 2017-12-21
KR102414558B1 (en) 2022-06-29
JP2022088417A (en) 2022-06-14
KR20180133493A (en) 2018-12-14
AU2017252527A1 (en) 2018-11-08
US20210147538A1 (en) 2021-05-20
US20200377606A1 (en) 2020-12-03
US10941201B2 (en) 2021-03-09
CA3021328A1 (en) 2017-10-26
MX2018012757A (en) 2019-06-24
US10865244B2 (en) 2020-12-15

Similar Documents

Publication Publication Date Title
SG11201808821WA (en) Agonistic antibodies that bind human cd40 and uses thereof
SG11201907299XA (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201810034XA (en) ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
SG11201907855QA (en) Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
SG11201901126UA (en) Combination therapy for cancer
SG11201900501RA (en) Cannabis composition
SG11201907427YA (en) Engineered transferrin receptor binding polypeptides
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201806453TA (en) Improved blood-brain barrier endothelial cells derived from pluripotent stem cells for blood-brain barrier models
SG11201408501UA (en) Preparation, uses and solid forms of obeticholic acid
SG11201807770RA (en) Sequence arrangements and sequences for neoepitope presentation
SG11201804589TA (en) Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
SG11201906947SA (en) Antibodies to alpha-synuclein and uses thereof
SG11201808125RA (en) Methods for solid tumor treatment
SG11201907646YA (en) Proteins binding her2, nkg2d and cd16
SG11201909303TA (en) Point of delivery cold slurry generation
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201804123VA (en) Modulators of kv3 channels to treat pain
SG11201806121PA (en) Ror2 antibody compositions and related methods
SG11201900665VA (en) Cannabis composition
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same